Usefulness of Continuous Glucose Monitoring in MODY Diagnosis

CompletedOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

January 1, 2025

Study Completion Date

January 31, 2025

Conditions
Type 1 DiabetesMODY
Interventions
DEVICE

Intermittenly scanned continuous glucose monitoring

"Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre) and meeting the glycometric data criteria:~* Time in range 70-180 mg/L \>70%~* Glycemic management index \<7%~* Coefficient of variation \<36%"

OTHER

MODY genetic diagnostic test

"Those patients fulfilling the glycometric data criteria and with clinical MODY suspicion:~* diagnosis before 35 years of age~* first-degree family history of diabetes.~* negative pancreatic autoimmunity (Ac GAD, IA-2A and Ac ZnT8)~* preserved pancreatic beta cell function defined as C-peptide \> 0.2 ng/mL in the presence of plasma glycemia \>140 mg/dL).~Those patients who meet the previous criteria will proceed to the MODY genetic diagnostic test."

Trial Locations (9)

13300

Valdepeñas General Hospital, Valdepeñas

13500

Santa Barbara Hospital, Puertollano

13600

La Mancha-Centro Hospital, Alcázar de San Juan

16002

Virgen de la Luz University Hospital, Cuenca

19002

Guadalajara University Hospital, Guadalajara

29010

Maria Jose Picon, Málaga

45007

Toledo University Hospital, Toledo

45600

Virgen del Prado Hospital, Talavera de la Reina

02006

Albacete University Hospital, Albacete

All Listed Sponsors
lead

Castilla-La Mancha Health Service

OTHER